1. bookAHEAD OF PRINT
Detalles de la revista
License
Formato
Revista
eISSN
2501-062X
Primera edición
30 Mar 2015
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

A Review of Transthyretin Cardiac Amyloidosis

Publicado en línea: 21 Oct 2022
Volumen & Edición: AHEAD OF PRINT
Páginas: -
Recibido: 06 Oct 2022
Detalles de la revista
License
Formato
Revista
eISSN
2501-062X
Primera edición
30 Mar 2015
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. PLUMADORE E, LOMBARDO L, AND CABRAL KP. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. Am J health-Syst Pharm. 2022; 79:52-62.10.1093/ajhp/zxab35634491302 Search in Google Scholar

2. PERFETTO F, ZAMPLERI M, FUMAGALLI C, ALLINOVI M, CAPPELLI F. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Internal and Emergency Medicine. 2022; 17:957-969.10.1007/s11739-022-02958-2913584535325395 Search in Google Scholar

3. YAMAMOTO H, YOKOCHI T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019; 6:1128-1139.10.1002/ehf2.12518698927931553132 Search in Google Scholar

4. GILLMORE JD, REILLEY MM, COATS CJ, COOPER R, COX H, COYNE MR, et al. Clinical and genetic evaluation of people with or without risk of hereditary ATTR amyloidosis: An expert opinion and consensus on best practice in Ireland and the UK. Adv Ther. 2022; 39:2292-2301.10.1007/s12325-022-02139-9912285735419651 Search in Google Scholar

5. JAIN A, ZAHRA F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Treasure Island, 2022. PMID 34662045. Search in Google Scholar

6. ANDO Y, ADAMS D, BENSON MD, BERK JL, PLANTE-BORDENEUVE V, COELHO T, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;1-13.10.1080/13506129.2022.205283835652823 Search in Google Scholar

7. OBI CA, MOSTERTZ WC, GRIFFIN JM, JUDGE DP. ATTR epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc J. 2022;18(2):17-26.10.14797/mdcvj.1066893238535414855 Search in Google Scholar

8. RIMBAS RC, BALINISTEANU A, MAGDA SL, VISOIU SI, CIOBANU AO, BEGANU E, et al. New advanced imaging parameters and biomarkers – a step forward in the diagnosis and prognosis of TTR cardiomyopathy. J Clin Med. 2022;11(2360):1-26.10.3390/jcm11092360910161735566485 Search in Google Scholar

9. GROGAN M, SCOTT CG, KYLE RA, ZELDENRUST ST, GERTZ MA, LIN G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-20.10.1016/j.jacc.2016.06.03327585505 Search in Google Scholar

10. DONNELLAN E, WAZNI OM, SALIBA WI, BARANOSWKI B, HANNA M, MARTYN M, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019;30(11):2427-2432.10.1111/jce.1418031515942 Search in Google Scholar

11. GILLMORE JD, DAMY T, FONTANA M, HUTCHINSON M, LACHMANN HJ, MARTINEZ-NAHARRO A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806.10.1093/eurheartj/ehx58929048471 Search in Google Scholar

12. OBICI L, BERK JL, GONZÁLEZ-DUARTE A, COELHO T, GILLMORE J, SCHMID HH, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153-162.10.1080/13506129.2020.173079032131641 Search in Google Scholar

13. STERN LK, PATEL J. Cardiac amyloidosis treatment. Methodist DeBakey Cardiovasc J. 2022;18(2):59-72.10.14797/mdcvj.1050893235935414852 Search in Google Scholar

14. TSCHOPE C, ELSANHOURY A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med. 2022;11(2148):1-14.10.3390/jcm11082148903157635456241 Search in Google Scholar

15. KAMDAR F, TAN CM, RODRIGUEZ ER, MOAZAMI N, HANNA M. Intramural coronary light-chain amyloidosis and left ventricular assist device implantation. The Journal of Heart and Lung Transplantation. 2020;39(10):1163-1164.10.1016/j.healun.2020.07.00532736937 Search in Google Scholar

16. Vyndaqel, Package insert. Pfizer Labs: 2020. Search in Google Scholar

17. Vyndamax, Package insert. Pfizer Labs: 2020. Search in Google Scholar

18. COELHO T, MAIA LF, MARTINS DA SILVA A, WADDINGTON CRUZ M, PLANTE-BORDENEUVE A, LOZERON P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.10.1212/WNL.0b013e3182661eb1409887522843282 Search in Google Scholar

19. MAURER MS, SCHWARTZ JH, GUNDAPANENI B, ELLIOTT PM, MERLINI G, WADDINGTON-CRUZ M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.10.1056/NEJMoa180568930145929 Search in Google Scholar

20. BERK JL, DYCK PJ, OBICI L, ZELDENRUST SR, SEKIJIMA Y, YAMASHITA T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011; 18(sup1):196–192.10.3109/13506129.2011.57435407321838485 Search in Google Scholar

21. ADAMS D, GONZALEX-DUART A, O’RIORDAN WD, YANG CC, UEDA M, KRISTEN AV, et al. Patisiran, an RNAi therapeutic, for hereditarytransthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21.10.1056/NEJMoa171615329972753 Search in Google Scholar

22. HABTEMARIAM BA, KARSTEN V, ATTARWALA H, GOEL V, MELCH M, CLAUSEN VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372–382.10.1002/cpt.197432599652 Search in Google Scholar

23. BENSON MD, WADDINGTON-CRUZ M, BERK JL, POLYDEFKIS M, DYCK PJ, WANG AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.29972757 Abierto DOISearch in Google Scholar

24. JUDGE DP, HEITNER SB, FALK RH, MAURER MS, SHAH SJ, WITTELES RM, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285-295.10.1016/j.jacc.2019.03.01230885685 Search in Google Scholar

25. GAMEZ J, SALVADO M, REIG N, SUNE P, CASASNOVAS C, ROJAS-GARCIA R, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(.). Amyloid. 2019;26(2):74–84.10.1080/13506129.2019.159770231119947 Search in Google Scholar

26. SUHR O, GROGAN M, MARTINS DA SILVA A. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 AAN annual meeting abstracts. Neurology. 2021;96(22): e2783–e2788.10.1212/WNL.0000000000012044 Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo